The Bristol Myers Squibb story
What drives Bristol Myers Squibb, what its price assumes and what could change the story, written from its own filings.
- Newer brands lead. In the quarter to June 2026, Growth Portfolio revenue rose 15% to $7.6 billion, exceeding Legacy Portfolio revenue of $5.4 billion.
- Eliquis still matters. Bristol Myers Squibb raised its 2026 worldwide Eliquis revenue growth outlook to 20% to 25%, even as generic competition eroded other legacy medicines.
- Cash supports the transition. Free cash flow was $11.4 billion over the last twelve months, while debt stood at $43.1 billion at the end of June 2026.
